期刊
INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 11, 期 -, 页码 6103-6121出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S112432
关键词
nanovaccine; dendritic cells; GalCer; inhalable vaccine
资金
- NIH [RO1CA16700, RO1AI042284]
- National Center for Advancing Translational Sciences, under the VICTR CTSA grant [UL1 RR024975-01, 2UL1 TR000445-06]
- Vanderbilt-Ingram Cancer Center Thoracic Program Initiative
- VA Merit Award [BX001444]
- Vanderbilt Ingram Cancer Center [P30 CA68485]
- Vanderbilt Digestive Disease Research Center [DK058404]
The present study investigated the immunoenhancing property of our newly designed nanovaccine, that is, its ability to induce antigen-specific immunity. This study also evaluated the synergistic effect of a novel compound PBS-44, an alpha-galactosylceramide analog, in boosting the immune response induced by our nanovaccine. The nanovaccine was prepared by encapsulating ovalbumin (ova) and an adjuvant within the poly(lactic-co-glycolic acid) nanoparticles. Quantitative analysis of our study data showed that the encapsulated vaccine was physically and biologically stable; the core content of our nanovaccine was found to be released steadily and slowly, and nearly 90% of the core content was slowly released over the course of 25 days. The in vivo immunization studies exhibited that the nanovaccine induced stronger and longer immune responses compared to its soluble counterpart. Similarly, intranasal inhalation of the nanovaccine induced more robust antigen-specific CD8(+) T cell response than intraperitoneal injection of nanovaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据